The Society of Thoracic Surgeons Practice Guideline Series: Aspirin and Other Antiplatelet Agents During Operative Coronary Revascularization (Executive Summary)*

Ferraris, Victor A.; Ferraris, Suellen P.; Moliterno, David J.; Camp, P.; Walenga, Jeanine M.; Messmore, Harry L.; Jeske, Walter; Edwards, Fred H.; Royston, David; Shahian, David M.; Peterson, Eric D.; Bridges, Charles R.; Despotis, George J.

doi:10.1016/j.athoracsur.2005.01.008

Cited by 134 publications

(75 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Decisions about preoperative aspirin therapy in patients undergoing CABG are made widely on the basis of individual and institutional experiences [11][12][13]. Actually, the American Heart Association, American College of Cardiology [18], The Society of Thoracic Surgeons (STS) [19], and the European Association for Cardio-Thoracic Surgery [20] even make different recommendations about when preoperative aspirin therapy should be terminated, ranging between 2 and 10 days before elective cardiac operations.…”

mentioning

confidence: 99%

Preoperative Aspirin Use and Its Effect on Adverse Events in Patients Undergoing Cardiac Operations

Huang

Donneyong

Trivedi

et al. 2015

The Annals of Thoracic Surgery

View full text Add to dashboard Cite

mentioning

confidence: 99%

Preoperative Aspirin Use and Its Effect on Adverse Events in Patients Undergoing Cardiac Operations

Huang

Donneyong

Trivedi

et al. 2015

The Annals of Thoracic Surgery

View full text Add to dashboard Cite

“…As long as clopidogrel was stopped 5 days prior to CABG there was no increase in risk of life-threatening bleeding. The CLARITY-TIMI trial and the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trials demonstrated similar improved outcomes without increased risk of bleeding in patients who underwent CABG after being treated with clopidogrel (Ferraris, Ferraris et al 2005). …”

Section: Wwwintechopencommentioning

confidence: 99%

Coronary Bypass Grafting in Acute Coronary Syndrome: Operative Approaches and Secondary Prevention

Huddleston¹,

Trachiotis²

2012

Acute Coronary Syndromes

View full text Add to dashboard Cite

“…Current guidelines recommend that aspirin be continued until the time of surgery as RCTs have indicated that, although this increases blood loss marginally, there are no serious adverse events attributable to this blood loss and there are clear benefits in terms of fewer adverse cardiovascular events prior to surgery. 60 Observational analyses demonstrate more severe bleeding and adverse events attributable to platelet inhibition with DAPT relative to aspirin alone 61,62 and current guidelines (class I recommendation, evidence level B) recommend that P2Y 12 receptor antagonists be stopped 3-5 days prior to surgery. 24 This empirical approach is not without risk; many patients may be left at increased risk of adverse cardiovascular events prior to surgery and this is not detected by observational studies that commonly analyse events from surgery, a form of lead time bias.…”

Section: Antiplatelet Agentsmentioning

confidence: 99%

“…For the dual-therapy subgroup, current practice guidelines suggest withdrawal of the P2Y 12 blocker approximately 3-5 days before cardiac surgery but continuation of aspirin up to the day of surgery. 24,60 In practice, the duration of withdrawal varies between 0 and 7 days before …”

Section: The Coptic a Studymentioning

confidence: 99%

Diagnostic and therapeutic medical devices for safer blood management in cardiac surgery: systematic reviews, observational studies and randomised controlled trials

Murphy

Mumford

Rogers

et al. 2017

Programme Grants Appl Res

View full text Add to dashboard Cite

This report should be referenced as follows:Murphy GJ, Mumford AD, Rogers CA, Wordsworth S, Stokes EA, Verheyden V, et al. Diagnostic and therapeutic medical devices for safer blood management in cardiac surgery: systematic reviews, observational studies and randomised controlled trials. Programme Grants Appl Res 2017;5(17). Programme Grants for Applied ResearchISSN 2050-4322 (Print) ISSN 2050-4330 (Online) This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: journals.library@nihr.ac.ukThe full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Programme Grants for Applied Research journalReports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Programme Grants for Applied Research programmeThe Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-forapplied-research.htm This reportThe research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0407-10384. The contractual start date was in July 2008. The final report began editorial review in July 2016 and was accepted for publication in April 2017. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not ...

show abstract

The Society of Thoracic Surgeons Practice Guideline Series: Aspirin and Other Antiplatelet Agents During Operative Coronary Revascularization (Executive Summary)*

Cited by 134 publications

References 41 publications

Preoperative Aspirin Use and Its Effect on Adverse Events in Patients Undergoing Cardiac Operations

Preoperative Aspirin Use and Its Effect on Adverse Events in Patients Undergoing Cardiac Operations

Coronary Bypass Grafting in Acute Coronary Syndrome: Operative Approaches and Secondary Prevention

Diagnostic and therapeutic medical devices for safer blood management in cardiac surgery: systematic reviews, observational studies and randomised controlled trials

Contact Info

Product

Resources

About